2013 annual financial data
Halozyme Therapeutics 2013 Operating margin
Direct answer
Operating margin was -146.78%.
Operating income was -80,433,637 USD and net income was -83,478,551 USD.
Operating cash flow was -49,339,479 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 54,799,447 USD
- Operating income
- -80,433,637 USD
- Net income
- -83,478,551 USD
- Operating cash flow
- -49,339,479 USD